• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

    12/30/24 7:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRNS alert in real time by email

    Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/

    The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, approved by the U.S. Food and Drug Administration (FDA) in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.

    Transaction rationale and details in brief:

    • Adds global rights to ZTALMY, a commercial-stage rare neurology medicine approved by FDA, the European Commission (EC), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Medicines Product Administration (NMPA) in China with potential for further approvals worldwide.
    • Accelerates Immedica's growth into the North American market, providing an immediate revenue-generating rare disease product and an experienced commercial team upon closing of the transaction.
    • Acquisition is expected to accelerate Immedica's revenue growth, adding a commercial-stage asset in the United States, with the potential for further expansion globally.
    • Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for USD 0.55 per share, corresponding to an implied enterprise value of approximately USD 151 Million.
    • Transaction is expected to close in Q1 2025.

    "The acquisition of Marinus represents a transformative step in Immedica's journey to further strengthen our position as a leading rare disease company. By adding ZTALMY to our portfolio, we significantly strengthen our capabilities and expand our presence in the United States, marking a new chapter in our mission to deliver impactful therapies for underserved patient populations," said Anders Edvell, M.D. Ph.D. and Chief Executive Officer of Immedica.

    "Immedica is dedicated to addressing significant unmet medical needs in rare diseases, ensuring patients receive the innovative treatments they deserve. Within CDD, patients with refractory seizures face particularly challenging circumstances due to insufficiently effective existing therapies. The addition of ZTALMY allows us to offer a differentiated solution, with the potential to improve care and outcomes for these patients," he concluded.

    "I am proud of the dedication and passion of our team at Marinus, which allowed us to deliver the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years of age and older," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a shared commitment to improving the lives of rare disease patients, this acquisition is expected to enable ZTALMY to make an even greater impact on patients, while providing meaningful value for Marinus' stockholders."

    Transaction details

    Under the terms of the merger agreement, Immedica, through a wholly owned, direct subsidiary, will initiate a tender offer to acquire all the outstanding shares of Marinus common stock for a cash purchase price of USD 0.55 per share, representing a premium of 48% based on Marinus' closing share price as of December 27th and a premium of 97%, based on the 30-day volume-weighted average price of USD 0.28 per share preceding the announcement of the transaction. The Board of Directors of Marinus has unanimously approved the transaction and recommended that the stockholders of Marinus tender their shares in the tender offer. Immedica has received an undertaking from each director and named executive officer of Marinus to tender their respective shares in favor of the transaction.

    The transaction represents the culmination of Marinus' review of strategic alternatives, which it announced on October 24, 2024, with the goal of maximizing value for its stockholders.

    The closing of the tender offer will be subject to customary conditions, including the tender of shares which represent at least a majority of the total number of Marinus' outstanding shares of common stock. Upon the successful completion of the tender offer, Immedica would acquire any shares of Marinus' common stock not tendered through a second-step merger effected for the same per share consideration. The transaction is expected to close in Q1 2025.

    Advisors

    MTS Health Partners LP is acting as Immedica's exclusive financial advisor in connection with the transaction. Gibson, Dunn & Crutcher LLP is acting as legal counsel to Immedica and Fuchs Patentanwälte Partnerschaft mbB is acting as intellectual property counsel on this transaction, Barclays Capital Inc. is acting as Marinus´ exclusive financial advisor in connection with the transaction. Hogan Lovells LLP is acting as legal counsel to Marinus on this transaction.

    About ZTALMY® (ganaxolone) oral suspension

    ZTALMY (ganaxolone) is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is a prescription medicine that has been approved by the U.S. FDA, EC, the MHRA, and the China NMPA for appropriate patients with CDKL5 deficiency disorder.

    U.S. Prescribing Information for ZTALMY® (ganaxolone) oral suspension CV.

    European Union Summary of Product Characteristics for ZTALMY.

    About Marinus Pharmaceuticals

    Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

    About Immedica

    Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

    Immedica was founded in 2018 and employs today around 130 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo. For more information visit www.immedica.com

    Important information

    The tender offer for the outstanding shares of common stock of Marinus Pharmaceuticals, Inc. referenced in this press release has not yet commenced. This document is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities of Marinus', nor is it a substitute for the tender offer materials that Immedica and Matador Subsidiary, Inc., a Delaware corporation and direct, wholly owned subsidiary of Immedica ("Purchaser") will file with the U.S. Securities and Exchange Commission (the "SEC"), upon commencement of the tender offer. The solicitation and offer to buy the shares of Marinus' common stock will only be made pursuant to an Offer to Purchase and related tender offer materials that Parent and the Purchaser intend to file with the SEC. At the time the tender offer is commenced, Immedica and Purchaser will file a Tender Offer Statement on Schedule TO and related materials, including, an offer to purchase, a letter of transmittal and other related documents with the SEC, and thereafter Marinus will file a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Marinus, Immedica and Purchaser intend to mail these documents to the stockholders of Marinus. Marinus' stockholders and other investors are urged to read carefully the tender offer materials (including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents) and the Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9, and any amendments or supplements thereto, when they become available because they will contain important information that holders of Marinus' securities and other investors should consider before making any decision with respect to the tender offer. The Offer to Purchase, the related letter of transmittal, and certain other tender offer documents, as well as the Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9, will be made available to all stockholders of Marinus at no expense to them and will also be made available for free at the SEC's website at www.sec.gov. Copies of the documents filed with the SEC by Marinus will be available free of charge on Marinus' website at https://ir.marinuspharma.com/investors/ or by contacting Marinus' investor relations by email at [email protected].

    Forward-looking statements

    This press release contains forward-looking statements related to Immedica, Marinus and the proposed acquisition of Marinus by Immedica (the "Transaction") that involve risks and uncertainties and reflect each of Immedica's and Marinus' judgment as of the date of this press release. These forward-looking statements generally are identified by words such as "believe," "can," "could", "seek", "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "might", "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, many of which are outside of Immedica's and Marinus' control. These forward-looking statements include, without limitation, statements regarding: the timing of the Transaction and when and whether the Transaction ultimately will close; the potential contributions the Transaction is expected to bring to Immedica; the expected impact on Immedica's future financial and operating results; Marinus' plans, objectives and expectations and intentions; the financial condition, results of operations and respective businesses of Marinus and Immedica; and any potential strategic benefits, synergies or opportunities expected as a result of the proposed Transaction. Many factors could cause actual future events to differ materially from Immedica's and Marinus' expectations, including, without limitation: the risk that the conditions to the closing of the Transaction are not satisfied, including the risk that Immedica may not receive sufficient number of shares tendered from Marinus' stockholders to complete the tender offer; the possibility that competing offers will be made; litigation relating to the Transaction; uncertainties as to the timing of the consummation of the Transaction and the ability of each of Immedica, Purchaser or Marinus to consummate the Transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement entered into between the companies; other business effects, including the effects of industry, economic or political conditions outside of the companies' control; the impact of competitive products and pricing; the effect of the announcement or pendency of the Transaction on Immedica's or Marinus' ability to retain and hire key personnel; competitive responses to the Transaction; unexpected costs, charges or expenses resulting from the Transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction; Immedica's ability to achieve the growth prospects and synergies expected from the Transaction, as well as delays, challenges and expenses associated with integrating Marinus with its existing businesses; legislative, regulatory and economic developments; and other risks described in Immedica's and Marinus' respective prior press releases and listed under the heading "Risk Factors" in Marinus' reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Marinus and the Schedule TO and related tender offer documents to be filed by Immedica and Purchaser prior to the completion of the Transaction. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Investors are cautioned not to put undue reliance on forward-looking statements, and each of Immedica and Marinus assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Neither Immedica nor Marinus gives any assurance that either Immedica or Marinus will achieve its expectations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241230307666/en/

    Get the next $MRNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRNS

    DatePrice TargetRatingAnalyst
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    8/14/2024Buy → Neutral
    Ladenburg Thalmann
    4/16/2024$20.00 → $2.00Outperform → Neutral
    Robert W. Baird
    4/15/2024$24.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    8/11/2023$14.00 → $9.00Outperform → Perform
    Oppenheimer
    1/20/2023$23.00Outperform
    RBC Capital Mkts
    12/20/2021$32.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $MRNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

      Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty

      12/30/24 7:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin

      11/12/24 4:00:00 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

      Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as

      10/24/24 8:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

      15-12G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

      2/21/25 8:00:27 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

      SCHEDULE 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      2/14/25 4:00:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

      EFFECT - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

      2/14/25 12:15:08 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:11:48 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

      9/23/24 7:37:13 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral

      8/14/24 7:42:32 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously

      4/16/24 8:12:28 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. "Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invalu

      5/17/23 4:01:00 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. "With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital

      4/18/23 7:01:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:19:58 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:19:21 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:18:26 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/15/24 10:35:20 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

      SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 6:39:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 3:04:48 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Financials

    Live finance-specific insights

    See more
    • Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

      8/13/24 7:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

      7/30/24 8:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care